Individualized therapy in multiple myeloma: are we there?

Area of Science:

• Hematology
• Oncology
• Genomics

Background:

• Multiple myeloma (MM) is a complex plasma cell disorder with variable clinical courses.
• Despite new therapies, a significant subset of high-risk MM shows resistance to treatment.
• Existing staging systems like Durie-Salmon and ISS provide prognostic information.

Purpose of the Study:

• To highlight the need for integrating diverse data for personalized MM treatment.
• To identify opportunities for refining risk stratification in multiple myeloma.
• To explore the potential of combined data for targeted therapeutic strategies.

Main Methods:

• Review of current risk stratification models in multiple myeloma.
• Analysis of cytogenetic and gene expression profiling for disease aggressiveness.
• Evaluation of minimal residual disease (MRD) assessment and imaging for relapse risk.

Main Results:

• Current models offer prognostic insights but do not fully address high-risk MM refractory cases.
• Cytogenetics, gene expression, MRD, and imaging provide crucial data for risk assessment.
• A gap exists in integrating these multifaceted data points for individualized treatment.

Conclusions:

• Integrating clinical, genomic, and imaging data is crucial for advancing multiple myeloma care.
• Developing algorithms to combine these data can inform personalized therapeutic interventions.
• This approach holds promise for improving outcomes in high-risk and refractory multiple myeloma patients.